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The innate immune sensor RIG-I responds to infection by binding to viral double-stranded RNA
(dsRNA). In this issue of Cell, Kowalinski et al. (2011) and Luo et al. (2011) reveal the structure of
RIG-I, and in combination with functional analyses, they show how RIG-I recognizes viral RNA to
initiate signaling and a type I interferon response.The innate immune response to viral in-
fection is initiated by the recognition of vi-
ral nucleic acids in an infected cell (O’Neill
and Bowie, 2010). RIG-I is a key intracel-
lular receptor that detects viral double-
stranded RNA (dsRNA) and launches a
signaling pathway that culminates in the
induction of antiviral type I interferons.
RIG-I is activated by a number of viruses,
including measles, influenza, and hepa-
titis C, and has a nonredundant role in
antiviral immunity (Kato et al., 2006).
Two papers in this issue of Cell
(Kowalinski et al., 2011; Luo et al., 2011)
describe precisely how RIG-I works. The
studies support a model in which RIG-I
functions as a nanomachine that re-
sponds to binding of ATP and dsRNA
with a conformational change, which one
author terms a ‘‘powerstroke,’’ to unleash
the caspase activation and recruitment
domains (CARDs) for downstream sig-
naling (Figure 1).
RIG-I is a superfamily 2 (SF2) helicase
that features two N-terminal tandem
CARDs, a DExH-box helicase domain,
and a C-terminal domain (CTD), which in
the resting state has been shown to
repress the function of RIG-I (Figure 1).
RNA binding activates RIG-I, and it asso-
ciates with blunt end 50triphosphate RNA
(18–20 nucleotides long), as well as with
longer dsRNA (greater than 200 nucleo-
tides) (Hornung et al., 2006; Kato et al.,
2008). RNA binds to both the CTD and
the helicase domain. Binding is thought
to stimulate the ATPase activity of the heli-
case domain, triggering a conformational
change that exposes the masked CARDs
(Gee et al., 2008). The available CARDsthen recruit the E3-ligase tripartite motif-
containing 25 (TRIM25) that modifies the
domains with K63-linked polyubiquitin
chains. Unanchored K63-linked ubiquitin
chains also associate with the CARDs
(Zeng et al., 2010). The formation of these
CARD-associated chains is essential for
recruitment of the adaptor protein MAVS,
which aggregates in the outer mitochon-
drial membrane and ultimately promotes
the induction of type I interferons.
The importance of the RIG-I pathway
can be seen from the fact that viral
proteins target it in order to evade the
host immune response (Bowie and Unter-
holzner, 2008). For example, NS2 protein
of respiratory syncytial virus binds RIG-I
directly, NS1 from influenza interferes
with TRIM25, and the hepatitis C virus
protease cleaves and inactivates MAVS.
To crack the structure of RIG-I, Cusack
and colleagues (Kowalinski et al., 2011)
focused on constructs from duck RIG-I
(dRIG-I) representing the free, resting (or
autorepressed), and activated states,
whereas Pyle and coworkers looked at
human RIG-I lacking the CARDs, which
forms a more intermediate activated state
(Luo et al., 2011). The overall structures,
perhaps unsurprisingly, reveal many simi-
larities. A highly interesting feature is in
the helicase domain, known to contain
two helicase RecA-like domains (Hel1
and Hel2) together with a domain inserted
into Hel2, termed Hel2i (Figure 1). This key
region forms a long ‘‘elbow’’-like structure
that extends from Hel2, folds back to
interact with Hel1, and then connects to
the CTD seen for the human protein and
in one of the duck RIG-I structures. FromCell 147sequence homology, this arrangement is
likely to be conserved with the other
RIG-I-like receptors, MDA-5 and LGP2.
In the free state seen for the dRIG-I heli-
case domain in the absence of RNA and
ATP, the domain is open and flexible
(Luo et al., 2011). The CTDwould presum-
ably be available to interact with RNA.
Initial capture of 50triphosphate dsRNA
by the CTD would then increase the
concentration of dsRNA in the vicinity of
the helicase. Subsequent cooperative
binding of dsRNA and ATP causes a
dramatic change in conformation, with
the three helicase subdomains all moving
relative to each other (Kowalinski et al.,
2011). This rearrangement brings Hel1
and Hel2 into close contact, creating a
high-affinity complex between dsRNA
and the helicase domain with a common
conformation appearing in both studies
(Kowalinski et al., 2011; Luo et al., 2011).
The structures also reveal a wealth of
information on the interaction between
the proteins and dsRNA. RIG-I completely
surrounds the dsRNA molecule and en-
closes it in a network of interactions.
Both dRIG-I and the human protein cover
a region of 9–10 bp along the dsRNA. Hel1
faces the minor groove of the dsRNA and
interacts with the RNA backbone of both
strands, and the Hel2i domain contributes
significantly to RNA binding. A notable
comparator here is TLR3, another impor-
tant antiviral receptor. TLR3 binds dsRNA
as a dimer, with each monomer binding
to one side of the RNA duplex (Liu et al.,
2008). Also of note is the observation
that human RIG-I dimers are able to
interact with dsRNA that is 18 bp long,, October 14, 2011 ª2011 Elsevier Inc. 259
Figure 1. Model of RIG-I Activation by Viral RNA
(A) Schematic representation of the protein domains in RIG-I. Tandem CARDs are involved in downstream
signaling once RIG-I is activated by RNA binding. Helicases (Hel) 1 and 2 are conserved helicase RecA-like
domains, whereas Hel2i is an insertion in Hel2 that is required for dsRNA interactions. P, ‘‘pincer’’ domain;
CTD, carboxy-terminal domain.
(B) Activation of RIG-I. In the inactive state, the RIG-I CARDs are sequestered by the helicase domains and
are not available for signaling. The CTD has high affinity for 50triphosphate dsRNA and can capture viral
RNA containing this motif, increasing the local concentration of dsRNA and favoring its cooperative
binding with ATP to the helicase domains. Conformational changes upon RNA and ATP binding exert
a powerstroke, leading to a ligand-bound, closed helicase complex. The conformational switch pushes
the tandem CARDs away from the helicase complex, making them available to recruit TRIM25, which
leads to the local generation of CARD-associated free K63-linked polyubiquitin chains, an event known to
be essential for engagement ofMAVS and subsequent downstream signaling to type I interferon induction.
RNA-mediated RIG-I dimerization is also likely important for activation (not shown).with one RIG-I interacting with the first
nine nucleotides, and another RIG-I inter-
acting with the next nine (Luo et al., 2011).
This interaction between the RIG-I mono-
mers is driven by the RNA template rather
than by direct dimerization of the proteins.
The ‘‘elbow’’-like structure referred to
above, which connects Hel1 to the CTD,
can be described as a ‘‘pincer’’ that grips
an a-helical shaft that extends from Hel1
(Luo et al., 2011). The authors suggest
that this extension functions in a similar
fashion to the camshaft of an engine, facil-
itating mechanical communication be-
tween Hel1, Hel2, and the CTD and coor-260 Cell 147, October 14, 2011 ª2011 Elsevidinating the structural rearrangement in
the protein that occurs during the ‘‘power-
stroke’’ that follows ATP binding. The
pincer is proposed to be able to open
and close, or rotate around the shaft,
altering the orientations of Hel1 to Hel2
and CTD to Hel1. Kowalinski et al. (2011)
see this region as a bridging element
that contacts Hel1, although the specific
interactions differ. In either case, changes
in this structural element upon activation
would contribute to transmission of the
signal (RNA and ATP binding) to the
CARDs, releasing them from their autore-
pressed state.er Inc.How does the conformational change
in the helicase domain lead to the release
of the CARDs for interaction with MAVS?
In the resting state structure (Kowalinski
et al., 2011), CARD1 and CARD2 interact
in a head-to-tail manner, with the head
of CARD1 interacting with the tail of
CARD2, forming a rigid functional unit. In
this state, both CARDs interact with
Hel2i. CARD2’s contact with Hel2i would
block access for TRIM or K63-linked pol-
yubiquitin in this autorepressed state. The
structure of the activated complex (Kowa-
linski et al., 2011) shows that the confor-
mational change in the helicase domain
releases CARD2 from this constraint.
Effectively, the high-affinity ATP binding
to the helicase leads to a 55 residue long
linker between CARD2 and the helicase
domain pushing the CARDs out of the
structure as a powerstroke (Figure 1).
The modified CARDs would then be able
to interact with MAVS. Finally, ATP hydro-
lysis would loosen the helicase domain,
reverting the CARDs—now deubiquiti-
nated—to the autorepressed state.
Structural insight into the architecture of
RIG-I and the movements that enable it to
respond effectively to dsRNA triggers will
have far-reaching implications. The struc-
tures of RIG-I reported here provide us
with the first detailed account of a protein
in the SF2 Dicer-RIG-I clade. They may
therefore also prove useful in the effort to
uncover how Dicer functions in the gener-
ation of miRNAs. Moreover, given the role
of RIG-I in antiviral immunity, the struc-
tures also offer a starting point for the
effort to develop inhibitors or activators
of RIG-I. Overactivation of RIG-I could be
important in viral pathology, including
hepatitis C and influenza, and inhibitors
could have clinical utility in treating these
and other infections. Specific activation
on the other hand could be useful in
vaccine adjuvancy. These two studies
open the door for structural analyses of
the many other nucleic acid-sensing
proteins, which will provide us with
detailed insight on the molecular basis of
antiviral innate immunity.
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315–330.Why Does Morphine Make You Itch?
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Opioids such as morphine numb pain but often concomitantly induce itch. Liu et al. (2011) now
separate the sensation of itch from opioid-induced analgesia, showing that in a subset of spinal
neurons, morphine directly induces itch by signaling through a heteromer of opioid- and itch-medi-
ating G protein-coupled receptors.Itch, or pruritus, is defined as an un-
pleasant sensation that elicits the desire
or reflex to scratch (Ikoma et al., 2006).
Itch occurs under many pathological con-
ditions, such as atopic dermatitis, and is
a common side effect of many drugs, in-
cluding antibiotics, antifungal drugs, and
narcotic pain medications (Reich et al.,
2009). For example, the malaria drug
chloroquine induces itch by acting on
peripheral sensory neurons via a G
protein-coupled receptor, MrgprA3 (Liu
et al., 2009). Another example is opioid-
induced itch, which is most severe when
opioids are administered directly into the
spinal column via an epidural injection.
Spinal opioid-induced itch has been
assumed to arise as a consequence of
pain inhibition, but the underlying mecha-
nism has been largely unknown. In this
issue of Cell, a study by Liu et al. provides
compelling evidence that spinal opioid-
induced itch is evoked independently of
opioid-induced analgesia by signaling
through an opioid receptor splice isoform
expressed in itch-mediating spinal neu-
rons (Liu et al., 2011).The distinct sensations of itch and pain
are evoked by different stimuli and induce
discrete responses (scratching versus
withdrawal). However, interactions be-
tween these two sensations are well
known; various types of noxious stimuli
are able to inhibit itch, and inhibition of
pain may evoke itch (Ikoma et al., 2006).
It has been postulated that pain signals
have a dominant inhibitory effect on
itch signals. This selectivity model is sup-
ported by recent studies reporting attenu-
ated pain and enhanced itch behaviors
in mice whose neurotransmission is in-
activated in subsets of nociceptive sen-
sory neurons (Patel and Dong, 2010). As
the selectivity model predicts, opioid-
induced itch has been thought to arise
indirectly as a consequence of opioid-
induced analgesia.
The new study by Liu et al. explores
the molecular basis of morphine-induced
scratching (MIS) and analgesia (MIA) in
mice. Previous experiments had estab-
lished that both MIS and MIA are medi-
ated by m-opioid receptor (MOR) (Loh
et al., 1998; Matthes et al., 1996). Themouse Oprm gene encodes many splice
isoforms of MOR (Pan, 2005). Liu and col-
leagues used exon-specific siRNA knock-
down in vivo and identified MOR1D and
MOR1 isoforms to be specifically required
for itch and analgesia, respectively.
MOR1D is coexpressed with the gastrin-
releasing peptide receptor (GRPR), a G
protein-coupled receptor that marks
spinal cord neurons required for the
sensation of itch (Sun and Chen, 2007;
Sun et al., 2009). Both pharmacological
and genetic knockdown of GRPR resulted
in specific attenuation of MIS without
affecting MIA (Figure 1). The authors
show that MOR1D and GRPR physically
interact. Upon further investigation, they
provide functional evidence that these
two receptors cross-activate in only one
direction: MOR1D activation by morphine
results in GRPR activation, but not
vice versa. Providing potential therapeutic
insight, Liu and colleagues show that
a unique C-terminal peptide of MOR1D
attached to a plasma membrane-perme-
ating signal competes with endogenous
MOR1D for physical interaction with, October 14, 2011 ª2011 Elsevier Inc. 261
